DSMM XIX / HD8

Section NCT
Category Hematological neoplasms
Subcategory Multiple myeloma
Trial Type First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma
Description for laymen A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma
JSON Data { "short_title": "DSMM XIX / HD8", "data_mode": "910", "data_mode_number": "000000045", "official_title": null, "accrual_state": "running", "therapeutic_value": "not_applicable", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": "2022-000996-38", "general_contact_email": "sal-aml-register@ukdd.de", "general_contact_phone": "+49 351-45818380", "hauptpruefer_dd_name": null, "description_laie_de": "Eine randomisierte Nichtunterlegenheitsstudie der Phase III zur Bewertung der Induktionstherapie mit Lenalidomid, Bortezomib und Dexamethason mit entweder intraven\u00f6s oder subkutan verabreichtem Isatuximab bei transplantationsf\u00e4higen Patienten mit neu diagnostiziertem multiplem Myelom", "description_laie_en": "A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma", "description_expert_de": "Eine randomisierte Nichtunterlegenheitsstudie der Phase III zur Bewertung der Induktionstherapie mit Lenalidomid, Bortezomib und Dexamethason mit entweder intraven\u00f6s oder subkutan verabreichtem Isatuximab bei transplantationsf\u00e4higen Patienten mit neu diagnostiziertem multiplem Myelom", "description_expert_en": "A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma", "rechtsgrundlage_value": null, "phase_amg_value": null, "main_cat_id": 4, "sub_cat_id": 26 }
Settings
Short name 910-000000045